Envista Holdings (NVST) is back in focus after recent Q1 2026 results showed broad-based growth across its core dental categories, alongside a new stock repurchase plan and upcoming changes in the accounting leadership team.

The Q1 2026 update and the incoming Chief Accounting Officer come after a mixed share price stretch, with a 30 day share price return down 14.7% but a 1 year total shareholder return of 23.3%, suggesting recent momentum has cooled after a stronger rebound.

If you are weighing Envista against other ideas in healthcare, this can be a good moment to see how specialized dental exposure compares with broader medical technology and 39 healthcare AI stocks

With Q1 profit acceleration, a new US$300 million buyback authorization, and the stock trading close to sector valuation multiples, the key question is whether Envista still trades at a discount or if the market already reflects future growth.

Most Popular Narrative: 20% Undervalued

With Envista closing at $23.10 against a narrative fair value of $28.69, the current setup hinges on how fully the market prices in its earnings trajectory and margin story.

Increasing R&D investment (up 14% year-over-year) and successful launches of digital and AI-driven products (e.g., DTX Studio Clinic with AI, DEXIS CDCTs, Spark product line) enhance Envista's ability to capitalize on growing demand for digital dentistry, supporting both future revenue growth and gross margin expansion.

Want to understand why this fair value leans on modest revenue gains but much faster earnings growth and a rich future earnings multiple? The key assumptions blend steady top line expansion, firmer profit margins and a valuation profile usually reserved for faster growing sectors, all discounted back using a measured required return.

Result: Fair Value of $28.69 (UNDERVALUED)

However, this upside story still depends on successful execution in China, where procurement reforms pressure pricing and on managing tariff and FX headwinds that squeeze margins.

Another Way To Look At Valuation

Analysts see Envista as trading below their fair value, but the P/E ratio of 55.5x tells a different story. It sits well above the Medical Equipment industry at 25.3x and above a fair ratio of 29.2x, which points to meaningful valuation risk if sentiment cools.

For a closer look at how this pricing stacks up against peers and what the fair ratio gap could mean for future re rating, check the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mix of optimism and caution so far, it makes sense to check the underlying numbers yourself and not rely on any single narrative. To see what the current optimism is built on, take a closer look at the 4 key rewards

Looking for more investment ideas?

If Envista has sharpened your focus on quality, do not stop here. Your next strong idea might be one thoughtful screen away.

• Target quality at a discount by scanning our set of 49 high quality undervalued stocks that combine solid fundamentals with appealing prices.
• Prioritize resilience by reviewing 64 resilient stocks with low risk scores that aim to limit downside while still keeping you exposed to potential upside.
• Spot future standouts early by checking the screener containing 22 high quality undiscovered gems before the crowd fully pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.